Evidence map›Paper›PMID 33287192›Full record

ArticleMolecules (Basel, Switzerland)2020

Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity.

Ana Frangolho, Bruno E Correia, Daniela C Vaz, Zaida L Almeida, Rui M M Brito

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Molecular Mechanisms of Cardiac Amyloidosis.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Ana FrangolhoChemistry Department and Coimbra Chemistry Centre, University of Coimbra, 3004-535 Coimbra, Portugal.
Bruno E CorreiaChemistry Department and Coimbra Chemistry Centre, University of Coimbra, 3004-535 Coimbra, Portugal.
Daniela C VazChemistry Department and Coimbra Chemistry Centre, University of Coimbra, 3004-535 Coimbra, Portugal.
Zaida L AlmeidaChemistry Department and Coimbra Chemistry Centre, University of Coimbra, 3004-535 Coimbra, Portugal.ORCID 0000-0002-4097-2766
Rui M M BritoChemistry Department and Coimbra Chemistry Centre, University of Coimbra, 3004-535 Coimbra, Portugal.ORCID 0000-0001-9128-2557
University of Coimbra · PTÉcole Polytechnique Fédérale de Lausanne · CHInstituto Politécnico de Leiria · PTInternational Iberian Nanotechnology Laboratory · PT

Funding

Fundação para a Ciência e a Tecnologia UIDB/QUI/00313/2020Fundação para a Ciência e a Tecnologia UIDP/QUI/00313/2020
6 · The paper itself

Abstract

One of the molecular hallmarks of amyloidoses is ordered protein aggregation involving the initial formation of soluble protein oligomers that eventually grow into insoluble fibrils. The identification and characterization of molecular species critical for amyloid fibril formation and disease development have been the focus of intense analysis in the literature. Here, using photo-induced cross-linking of unmodified proteins (PICUP), we studied the early stages of oligomerization of human transthyretin (TTR), a plasma protein involved in amyloid diseases (ATTR amyloidosis) with multiple clinical manifestations. Upon comparison, the oligomerization processes of wild-type TTR (TTRwt) and several TTR variants (TTRV30M, TTRL55P, and TTRT119M) clearly show distinct oligomerization kinetics for the amyloidogenic variants but a similar oligomerization mechanism. The oligomerization kinetics of the TTR amyloidogenic variants under analysis showed a good correlation with their amyloidogenic potential, with the most amyloidogenic variants aggregating faster (TTRL55P > TTRV30M > TTRwt). Moreover, the early stage oligomerization mechanism for these variants involves stepwise addition of monomeric units to the growing oligomer. A completely different behavior was observed for the nonamyloidogenic TTRT119M variant, which does not form oligomers in the same acidic conditions and even for longer incubation times. Thorough characterization of the initial steps of TTR oligomerization is critical for better understanding the origin of ATTR cytotoxicity and developing novel therapeutic strategies for the treatment of ATTR amyloidosis.

Indexed as

AmyloidAmyloidosisBlood ProteinsEscherichia coliHumansKineticsPolymerizationPrealbuminProtein AggregatesRecombinant ProteinsAmyloidBlood ProteinsPrealbuminProtein AggregatesRecombinant ProteinsaggregationamyloidamyloidosisATTRdownhill polymerizationlinear oligomerizationtransthyretinTTRTTR variants

Identifiers

PMID33287192
PMCPMC7730986
OpenAlexW3109045139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.